What the research reports
View evidenceA controlled trial reported a 15.2% reduction in CT-measured visceral adipose tissue at week 26, compared with a 5.0% increase with placebo.
Image 01 / 01Research compound
Tesamorelin
GHRH analogue — approved indication exists · Phase 3
Research compoundCA$170.00
Tesamorelin/
CA$170.00
Key findings
Pooled Phase 3 work reported sustained CT-measured visceral-adipose-tissue reduction through week 52.
Where the evidence comes from
View evidenceTesamorelin findings shown here come from controlled and pooled trials in adults with HIV-associated lipodystrophy.
Falutz et al., NEJM, 2007 · PubMed · Falutz et al., JCEM, 2010 · PubMed
What's still open
Tesamorelin findings shown here remain specific to the cited HIV-associated lipodystrophy populations.
Falutz et al., NEJM, 2007 · PubMed · Falutz et al., JCEM, 2010 · PubMed
